Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevenar immunogenicity study in myeloma and chronic lymphocytic leukaemia
2005-003761-16Phase 4Completed
- Sponsor
- Central Manchester and Manchester Children's Hospitals NHS Trust
- Start
- Oct 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pneumococcal 7-valent conjugate vaccine in pneumococcal disease, sponsored by Central Manchester and Manchester Children's Hospitals NHS Trust. Primary endpoints: Immunogenicity by serotype-specific IgG levels, Change from baseline after 2 doses of Prevenar and 2 more. Started Oct 2005; status: completed.
02
Drugs
pneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2005-003761-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003761-16.